AstraZeneca Completes $2 Billion Investment in Summit Therapeutics to Advance Ivonescimab and ADC Cancer Combinations

AstraZeneca has successfully completed its $2 billion equity investment in Summit Therapeutics, solidifying a strategic alliance designed to advance ivonescimab—a potential first-in-class bispecific antibody targeting PD-1 and VEGF—in combination with antibody-drug conjugates (ADCs) across a variety of oncological indications.

Key Partnership and Clinical Development Goals

Bispecific Antibody Mechanism: Ivonescimab merges PD-1 immune checkpoint inhibition with the anti-angiogenic effects of VEGF blockade into a single molecule.
Sonesitatug Vedotin (Sone-Ve) Trials: AstraZeneca and Summit intend to evaluate Sone-Ve—a Claudin-18.2-targeting ADC—in combination with ivonescimab through newly initiated clinical trials focused on gastrointestinal cancers.
Broad Combination Programme: The collaboration will expand to test ivonescimab alongside additional AstraZeneca cancer medications and other ADCs.
Triple-Party Collaboration: A separate cooperative agreement between AstraZeneca, Daiichi Sankyo, and Summit Therapeutics will investigate the combination of Datroway (datopotamab deruxtecan) with ivonescimab across various tumour types, including lung and breast cancers.

Investment Structure and Equity Details

Share Acquisition: Under the agreement initially announced in September, AstraZeneca acquired roughly 109,000 shares of Summit preferred stock, which are convertible into common shares at a 1:1,000 ratio.
Ownership Stake: Post-completion, AstraZeneca holds rights matching approximately 12% of Summit Therapeutics’ outstanding common stock, or about 10.6% on a fully diluted basis.

Regulatory Status and Global Pipeline

Development Rights: Ivonescimab was originally created by Akeso Inc., with Summit holding exclusive development and commercialisation rights in major territories outside of China.
Current Approvals & Reviews: The therapeutic is already approved for specific non-small cell lung cancer (NSCLC) patients within China, and a Biologics License Application targeting EGFR-mutated NSCLC is currently under review by the U.S. FDA.
Phase III Trials: Beyond NSCLC, ivonescimab is undergoing Phase III evaluation across multiple additional cancer types, including:
- Small cell lung cancer
- Biliary tract cancer
- Bladder cancer
- Triple-negative breast cancer
- Head and neck squamous cell carcinoma
- Colorectal cancer
- Pancreatic cancer